Secukinumab receives FDA approval for psoriatic arthritis, ankylosing spondylitis

The Food and Drug Administration approved two new indications for the interleukin-17A inhibitor secukinumab (Cosentyx) – psoriatic arthritis in adults and ankylosing spondylitis in adults – on Jan. 15. These join the approval for moderate to severe plaque psoriasis in adults it received in January...
Source: Skin and Allergy News - Category: Dermatology Source Type: news